

## **Draft Guidance on Fluorouracil**

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

**Active ingredient:** Fluorouracil

**Form/Route:** Solution/Topical, 2%

### **I. Waiver option:**

- a. To qualify for a waiver of the in vivo bioequivalence study requirement under 21 CFR 320.22(b)(3), generic versions of Fluorouracil Topical Solution, 2% must contain the same active drug ingredient in the same concentration and dosage form as the Reference Listed Drug (RLD) and contain no inactive ingredient or other change in formulation from the RLD that may significantly affect systemic or local availability.
- b. For a topical drug product that differs from the RLD in inactive ingredients [as permitted by the chemistry, manufacturing and controls regulations for abbreviated new drug applications, 21 CFR 314.94(a)(9)(v)], the regulation specifies that the applicant must identify and characterize the differences and provide information demonstrating that the differences do not affect the safety or efficacy of the proposed drug product.

---

### **II. In Vivo option:**

**Recommended studies:** 1 study

Type of study: Bioequivalence (BE) Study with Clinical Endpoint

Design: Randomized, double blind, parallel, placebo-controlled in vivo

Strength: 2%

Subjects: Healthy males and nonpregnant females with clinically typical, visible, actinic keratoses (AK) on the face or bald scalp.

Additional comments: See recommendations for the BE Study with Clinical Endpoint in the posted Draft Guidance on Fluorouracil Cream/Topical, 5%.

---

**Analytes to measure (in appropriate biological fluid):** Not Applicable

**Bioequivalence based on (90% CI):** Clinical endpoint (in vivo option)

**Dissolution test method and sampling times:** Not Applicable